Overview
MDGL market data
Price History
MDGL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$12.85 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -25.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $342.73 – $615.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11.9B · P/B 21.94 · P/S 9.27.
Company News
8-K filing — MADRIGAL PHARMACEUTICALS, INC. (MDGL)SEC EDGAR · Aug 12, 2026, 12:18 PM
Madrigal Pharmaceuticals shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $605 price target.Benzinga · Aug 4, 2026, 6:50 PM
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga · Aug 4, 2026, 11:46 AM
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price TargetBenzinga · Aug 4, 2026, 9:29 AM
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962Benzinga · Aug 3, 2026, 12:05 PM
Madrigal Pharmaceuticals shares are trading lower. The company reported Q2 financial results.Benzinga · Jul 30, 2026, 12:56 PM
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M EstimateBenzinga · Jul 30, 2026, 11:02 AM
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587Benzinga · Jul 29, 2026, 5:45 PM
Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685Benzinga · Jul 27, 2026, 12:55 PM
Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark OfficeBenzinga · Jul 13, 2026, 12:03 PM